SkinBioTherapeutics plc SkinBiotix® technology successful in stability testing

Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented:

“Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start this month.”

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

SkinBioTherapeutics plc (LON: SBTX), a life science company focused on skin health, today provided an update to its announcement of 16 August 2018. The stability criteria required for its human study has been met and the Company expects to commence the study in September as planned.

Click to view all articles for the EPIC: SBTX
Or click to view the full company profile:

Are yoghurt facials the next beauty breakthrough?

13th March 2018

Lathering your skin with the same stuff you put on top of your breakfast might not seem like the way to get glowing skin but some are hailing it as a beauty breakthrough. Probiotics – the

Q&A with Dr Cath O’Neill Chief Executive Officer at Skinbiotherapeutics PLC (LON:SBTX)

6th March 2018

Skinbiotherapeutics’ Dr Cath O’Neill discusses how they have progressed since FY results, how their SkinBiotix technology works, the significance of the scale-up and the formulations, the next key milestones and the progress for possible commercial partners in this exclusive interview with DirectorsTalk

INTERVIEW: SkinBioTherapeutics Plc Positive Progress since October

1st March 2018

SkinBioTherapeutics Plc (LON:SBTX) CEO Dr. Cath O’Neill talks to DirectorsTalk about the progress made since FY results in October 17. Cath provides us with an update, reminds us what SkinBioTherapeutics does and how its SkinBiotix® technology

Probiotics & Skin: the next big thing in beauty?

27th February 2018

If we look back just a couple of decades, many people had not even heard the term ‘probiotic’, but awareness of ‘friendly bacteria’ has been gradually increasing, mainly due to the increased amount of scientific research

Increasing awareness of the benefits of using probiotics in skincare

23rd February 2018

DirectorsTalk caught up with Dr. Catherine O’Neill CEO of Skinbiotherapeutics PLC (LON:SBTX) for her thoughts on an article published by Daily Mail entitled “Forget ‘ingestible beauty’ – experts now claim lathering probiotics on your FACE is the

“SkinBioTherapeutics plc significant progress in the past six months” Dr. Cath O’Neill, CEO

21st February 2018

SkinBioTherapeutics plc (LON:SBTX) a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2017. — Significant progress in developing the SkinBiotix(R) technology; successful initial

Skinbiotherapeutics PLC Notice of interim results

16th February 2018

Skinbiotherapeutics PLC (LON:SBTX), a life sciences company focused on skin health, will publish its interim results for the six months to 31 December 2017 on 21 February 2018. SkinBioTherapeutics is a life science company focused on

Skinbiotherapeutics Appointment of Joint Broker

5th January 2018

Skinbiotherapeutics PLC (LON:SBTX), a life science company focused on skin health, announced today the appointment of Northland Capital Partners to act as the Company’s Joint Corporate Broker, alongside Turner Pope Investments, with immediate effect. Skinbiotherapeutics is

SkinBioTherapeutics Notification of first patent grant

1st December 2017

SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia. The patent granted covers the use of specific probiotic bacteria and lysates in

SkinBioTherapeutics plc platform passes additional external toxicity tests

9th November 2017

SkinBioTherapeutics plc LON:SBTX a life science company focused on skin health, has passed two additional and final third party cellular toxicity tests for its SkinBiotix(R) technology. The in vitro tests, for photo-toxicity (sensitivity to sunlight) and

SkinBioTherapeutics CEO Dr Cath O’Neill to present at investor evening

8th November 2017

Skinbiotherapeutics PLC (LON:SBTX), a life science company focused on skin health, has announced that Dr Catherine O’Neill, CEO, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd. The event will be

Dr Cath O’Neill Recognised as One of the Top 50 Female Leaders in UK Healthcare

2nd November 2017

Dr Cath O’Neill, Chief Executive Officer of SkinBiotherapetics PLC (LON:SBTX) caught up with Proactive Investors after being named one of healthcare’s top movers and shakers as part of BioBusiness’ 2017 50 Movers and Shakers report. Video source:

Skinbiotherapeutics Plc: Probiotics to replace antibiotics in wound healing?

18th October 2017

Did you know that bacteria have antibacterial properties? Its true. We spoke to Dr Catherine O’neill CEO of Skinbiotix Plc (LON:SBTX) who said, ‘Its worth remembering that penicillin, one of the first antibiotics to be used

Q&A with Dr. Catherine O’Neill Chief Executive Officer at Skinbiotherapeutics PLC (LON:SBTX)

6th October 2017

Skinbiotherapeutics’ Dr. Catherine O’Neill discusses passing third party cytotoxicity tests, their scientific update to the market & what’s next for the company in this exclusive interview with DirectorsTalk

SkinBioTherapeutics plc “starting initial discussions with partners”

5th October 2017

SkinBioTherapeutics plc (LON:SBTX) a life sciences company focused on skin health, has announced its full year results for the year to 30 June 2017. Key highlights — Research agreement with the University of Manchester for ‘development

SkinBioTherapeutics plc “Essential external validation passed” Dr Catherine O’Neill, CEO

3rd October 2017

SkinBioTherapeutics plc LON:SBTX, a life science company focused on skin health, has passed third party cellular toxicity tests for its SkinBiotix(R) technology, confirming previous in-house observations on its safety and applicability. Dr Catherine O’Neill, CEO of SkinBioTherapeutics,

SkinBioTherapeutics PLC Notice of Results

27th September 2017

SkinBioTherapeutics PLC (LON:SBTX) a life science company focused on skin health, will publish its full year results for the year to 30 June 2017 on Thursday, 5 October 2017. SkinBioTherapeutics is a life science company

Cosmetics: The next microbiome frontier

20th June 2017

“Love your bacteria.” That’s the tagline for Yun Probiotherapy’s line of skin cosmetics directed at those who have acne or athlete’s foot or who just want to keep their skin looking healthy. Yun’s product line, now

Be sure to check our sister interview main ratings news website